About Endogenous Bornavirus-like nucleoprotein 1
Endogenous Bornavirus-like nucleoprotein 1 (EBLN1) is a protein
from Homo sapiens identified by UniProt accession
P0CF75, 366 residues long.
MolForge cross-references it against 0 known binders and
21 disease associations.
Target properties
| Protein name | Endogenous Bornavirus-like nucleoprotein 1 |
| UniProt accession | P0CF75 |
| Gene | EBLN1 |
| Organism | Homo sapiens |
| Length | 366 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (21)
Diseases linked to this target (Open Targets).
- calcium measurement · score 0.44
- monocyte percentage of leukocytes · score 0.33
- lower urinary tract symptom · score 0.31
- benign prostatic hyperplasia · score 0.31
- lymphocyte:monocyte ratio · score 0.28
- lymphocyte count · score 0.27
- amyloid-beta measurement · score 0.27
- myeloid white cell count · score 0.23
- granulocyte percentage of myeloid white cells · score 0.19
- subcutaneous adipose tissue measurement · score 0.16
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P0CF75-F1 | alphafold | PREDICTED | 84.42 | — |
Amino-acid sequence (366 residues)
MSRPRNNPQT SSPQDSTKDG SSFHYFQGRF ELSGKSRQYP ADALEPQPGI GDVKVIEKAT KSMLDPAQRS HFYLVTPSLV FLCFIFDGLH KALLSVGVSK RSNIVIGNEN KETGTLYASK FEDVLPTFTA LEMSSILRHC CDLIGIAAGS SDPICTNSLQ VQRQFKAMMI SIGRPLHSES ADLLISYNAG PAIDWINSRP WVGGLMFTFL FGEFESPACE LLDQVKVVAS KAQMMTYYTV RMFLDQCVDG STALPAVVLE IPVFEQKKPL AKKVLGDFFE FGGVLRHPVI GVLSPQMFPN LATAANYWAK RRNSTFSGFE ALDIIPGSTI TFPVLQMASA QKISRGSDMD PYTLNILRGY GISGFE
Explore Endogenous Bornavirus-like nucleoprotein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets